

# Coronary artery disease in Europe: what are the genetic risk factors?

Mortality rates from coronary artery disease (CAD) in men in the UK and Germany are more than twice as high as those in Italy or Spain. In Germany, diseases of the heart and circulatory system are not only the most important cause of death but also the most important cause of reduced life expectancy due to premature death. The European Union recognises that premature coronary artery disease in Europe is a major health problem of great socio-economic impact. In both direct and indirect costs, ischaemic heart disease accounts for about 15% of all illness-related costs in Germany, coming second only to diseases of the digestive system (nearly 19%).

Although dietary habits and lifestyle differences may contribute in part to the differences in mortality rates from CAD between North and South Europe, genetic differences may predispose or protect one population more than another. Moreover, any gene loci that confer susceptibility to, or protection from, CAD may be quite different between north and south Europe. Knowledge of such susceptibility loci and their frequencies in the populations of north and south Europe would be of use in several major ways.

- It would allow us to assign personal risk on a much surer foundation than at present possible.
- Such high risk individuals could then be a target for preventive therapies which would eventually reduce the long-term social and economic burden of CAD in our European populations.
- It may point to critical environmental factors that interact with the genotype for development of the disease.
- Identifying such key environmental determinants from knowledge of the genes involved may aid in disease prevention both at the population and individual levels.
- New lines of therapy may be formulated once the defective genes are known by either replacing, modulating or blocking their gene products.

Our laboratory at St Bartholomew's Hospital provides the lead for a project to study the differences in frequency of coronary artery disease between north and south Europe. Participating cities are Cologne, Freiburg, Rome, Barcelona, Bratislava, London and

Cardiff. We will attempt to identify common genetic determinants for premature coronary artery disease and assess their possible interactions. The effects of genetic and environmental risk factors (smoking, dietary fat intake and blood pressure) are to be studied in relation to the age of clinical presentation and severity of coronary atherosclerosis assessed angiographically.

## Questions to be answered

- 1 Are any of the described genetic variants that have been related to the development of premature atherosclerosis found more frequently in subjects with CAD? Can new variants at other loci be identified as genetic risk factors?
- 2 Do such genetic determinants differ between north and south Europe in patients with premature CAD?
- 3 If so, what is the relative incidence of each of these mutations and its impact on the occurrence of CAD at each centre?
- 4 Do environmental risk factors such as smoking, dietary fat and alcohol intake, body mass index and blood pressure interact with genetic factors to accelerate the age of presentation or the severity of premature atherosclerosis as defined angiographically?

The work of the laboratory measurements (serum lipids, lipoprotein (a), and the genetic analyses including common variants at the Apo AI/CII/AIV gene cluster, the lipoprotein lipase gene, and the apolipoprotein E polymorphisms) are being shared among the participating European centres. There are regular discussions (by fax and E-mail) to ensure the progress of the project; and we all meet once yearly, usually to coincide with a European medical society meeting, to discuss issues and problems.

It is hoped that eventually identification of such susceptibility loci will provide new biological targets for active therapeutic intervention for this common disorder

## Acknowledgements

This project is supported by grant PL931211 of the Commission of the European Communities.

## Bibliography

- 1 Baert AE, Baig SS, Bardoux C, Fracchia GN, *et al.* *The European Union biomedical and health research.* Amsterdam: I O S Press, 1995.

D J GALTON, DSc, FRCP, *Professor of Human Metabolism*

J CAVANNA, PhD, *Senior Scientist*

A KAY, MSc, *Research Assistant*

Q ZHANG, MSc, *Research Assistant*

*Department of Human Metabolism and Genetics,  
St Bartholomew's Hospital, London*

- 2 Assmann G, Schutte H. Primary prevention of coronary heart disease in the Federal Republic of Germany. In: Lewis B, Assmann G (eds). *The social and economic contexts of coronary prevention*. London: Current Medical Literature, 1990.
- 3 Zhang Q, Cavanna J, Winkleman B, Marz W, *et al*. Common genetic variants of lipoprotein lipase that relate to lipid transport in patients with premature coronary artery disease. *Clinical Genetics* (in press).
- 4 Leaman DM, Brower RW, Meester GT, Serruys B, Brand VD. Coronary artery atherosclerosis: severity of the disease and compromised left ventricular function. *Circulation* 1981;63:285-91.

Address for correspondence: Professor D J Galton, Department of Human Metabolism and Genetics, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE.

## International developments in health care

### A review of health systems in the 1990s

Edited by Roger Williams

In the last ten years or so it has become evident to all nations in the developed world that simply spending ever more of their gross domestic product on health care is not enough to meet the level of health care expected by their peoples. Moreover, the ageing of nations will place an increasingly heavy burden on the income-generating sections of their populations. Individual countries have attempted to improve the effectiveness and efficiency of their health care systems. Such attempts, not surprisingly, have been heavily influenced by political considerations. To give those more closely concerned with delivering medical care the opportunity to learn how different systems operate, and to debate and discuss among themselves their pros and cons, the Royal College of Physicians arranged a meeting on which the edited chapters and discussion sections of this book are based. Contributors were drawn from North America, the Commonwealth countries of Canada, Australia and New Zealand, from mainland Europe including France, the Netherlands, Germany and Sweden, and from the UK. They included health care planners, members of government, clinicians from hospitals and general practice and officers of the medical Royal Colleges.

#### CONTENTS

Preface by *Anthony J Culyer*

**PART 1 New Schemes in the Commonwealth** An introduction to the Commonwealth scene by *Robert Maxwell* ♦ Changed organisation in New Zealand by *Peter Martin* ♦ Australia's health reform by *Dallas Ariotti* ♦ Canada's health system: charting a new vision for the 21st century by *Rey D Pagtakhan*

**PART 2 Developments in health care in the United States of America** An introduction to the American scene by *Richard I Kitney* ♦ Health care reform in the United States by *Roz D Lasker* ♦ Attitudes of American physicians to health systems reform by *Clifton R Cleaveland*

**PART 3 Changes within Europe** Introduction to European health care systems by *John F Martin* ♦ Reforming the German health care system by *Michael Moran* ♦ Government plans in France by *Laurent Zylberberg* ♦ Restructuring health care in the Netherlands by *Kieke GH Okma* ♦ The effects of market mechanisms in a public health care system; the case of Sweden by *Johan Calltorp*

**PART 4 Health reforms in the United Kingdom** An introduction to the UK scene by *Roger Williams* ♦ Managed competition in health care by *Chris Ham* ♦ The way ahead by *Alan Langlands* ♦ Impact of the general practitioner as a fundholder by *David Colin-Thomé* ♦ Changes in hospital provision by *John R Bennett*

Price £15.00 (overseas £18.00). ISBN 1 86016 013 1

Soft cover, 165 pages.

Obtainable from the Royal College of Physicians and from bookshops



ROYAL COLLEGE OF PHYSICIANS OF LONDON